Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Return on Capital Employed for 5 consecutive years, with 0.66% as the latest value for Q3 2025.

  • Quarterly Return on Capital Employed rose 1118.0% to 0.66% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 0.66% through Sep 2025, up 1118.0% year-over-year, with the annual reading at 0.54% for FY2024, 69.0% up from the prior year.
  • Return on Capital Employed for Q3 2025 was 0.66% at Inhibikase Therapeutics, down from 0.53% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.24% in Q3 2021, with the low at 11.84% in Q3 2024.
  • Average Return on Capital Employed over 5 years is 1.57%, with a median of 0.67% recorded in 2022.
  • The sharpest move saw Return on Capital Employed plummeted -1069bps in 2024, then skyrocketed 1118bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.37% in 2021, then crashed by -114bps to 0.79% in 2022, then tumbled by -100bps to 1.58% in 2023, then soared by 62bps to 0.6% in 2024, then decreased by -10bps to 0.66% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.66%, 0.53%, and 0.44% for Q3 2025, Q2 2025, and Q1 2025 respectively.